Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5668467 | Journal of Hospital Infection | 2016 | 4 Pages |
Abstract
SummaryInpatients who had been in close contact with patients with influenza were given oseltamivir [75Â mg capsules once daily for adults or 2Â mg/kg (maximum of 75Â mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P=0.023] and 94% for influenza A (95% CI 61-99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
N. Ishiguro, R. Oyamada, Y. Nasuhara, T. Yamada, T. Miyamoto, S. Imai, K. Akizawa, T. Fukumoto, S. Iwasaki, H. Iijima, K. Ono,